{
    "clinical_study": {
        "@rank": "16439", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "After implementing PCI, temporary drug treatment is conducted.\n*Temporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotien llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, \u03b2-blocker, CCB, Diuretics, Statin, etc.)"
            }, 
            {
                "arm_group_label": "Treatment group 1", 
                "arm_group_type": "Experimental", 
                "description": "Within four weeks after performing PCI and bone marrow puncture, infarct coronary artery catheter is used to inject approximately 1\u00d710^6/kg (refer to usage/dosage according to mass) of human bone marrow-derived mesenchymal stem cells into the infarct coronary artery. Furthermore, temporary drug treatment is conducted."
            }, 
            {
                "arm_group_label": "Treatment group 2", 
                "arm_group_type": "Experimental", 
                "description": "Within four weeks after performing PCI and bone marrow puncture, infarct coronary artery catheter is used to inject approximately 1\u00d710^6/kg (refer to usage/dosage according to mass) of human bone marrow-derived mesenchymal stem cells into the infarct coronary artery. Furthermore, temporary drug treatment is conducted.\nHowever, among the human bone marrow-derived mesenchymal stem cell cultures obtained after bone marrow collection, the first batch of the stem cell cultures is stored, and after the first cell injection, the second cell injection is conducted within a month."
            }
        ], 
        "brief_summary": {
            "textblock": "Through the injection of Hearticellgram-AMI into acute myocardial infarction patients who\n      are the primary targets of the drug, long term efficacy in the improvement of the left\n      ventricle ejection fraction upon the first cell treatment is to be evaluated and compared\n      with the current existing treatments (temporary drug treatment)."
        }, 
        "brief_title": "RELIEF(A Randomized,Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial inFarction)", 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Between the ages of 20-70\n\n          2. Left Ventricular Ejection Fraction (LVEF) under 45%\n\n          3. Acute myocardial infraction patients fulfilling at least one of the given qualities,\n             through the use of an electrocardiogram (12-lead ECG) A. ST-segment elevation 0.1 mV\n             in two or more limb leads or B. 0.2 mV elevation in two or more contiguous precordial\n             leads , indicative of AMI\n\n          4. Anterior Wall MI\n\n          5. Patients who fulfill the above criteria and also have experienced successful\n             reperfusion\n\n          6. Patients who can consent to participate in this clinical trial personally, as well as\n             through a legal attorney\n\n        Exclusion Criteria:\n\n          1. Patients who have been diagnosed with malignant blood-related diseases (acute\n             myelocyte leukemia, acute lymphatic leukemia, non-Hodgkin's lymphoma, multiple\n             myeloma),  and have not improved\n\n          2. Patients with major aplastic anemia\n\n          3. Patients with solid cancers in their previous medical history (within 5 years)\n\n          4. Patients whose blood serum AST/ASL rates are more than three times the normal maximum\n             rate, and whose creatinine rates are more than 1.5 times the normal maximum rate (but\n             AST in myocardial infarction patients can temporarily rise, thus, as decided by the\n             researchers, if there is no damage to the liver function, the rise will not be taken\n             into consideration)\n\n          5. Patients who have implemented Coronary Artery Bypass (CAB)\n\n          6. Patients with chronic heart failure (patients with heart failure medical history at\n             least three months before the occurrence of acute myocardial infarction)\n\n          7. Patients who cannot proceed with cardiac catheterization\n\n          8. Patients who had been continuously taking large doses of steroids or antibiotics one\n             month prior to registration\n\n          9. Patients who had major surgical operations, organ biopsy, or significant external\n             injury as determined by the researcher, within three months before registration\n\n         10. Patients who have head injuries or other external injuries after the development of\n             myocardial infarction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "135", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652209", 
            "org_study_id": "PMC-BD-CT-P-003"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment group 1", 
                "Treatment group 2"
            ], 
            "intervention_name": "Hearticellgram-AMI", 
            "intervention_type": "Biological", 
            "other_name": [
                "Hearticellgram-AMI", 
                "(human bone marrow derived mesenchymal stem cells)"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 13, 2013", 
        "location": {
            "contact": {
                "email": "zzwan@pharmicell.com", 
                "last_name": "WanSeok Joo, Ph.D"
            }, 
            "contact_backup": {
                "email": "smpark@pharmicell.com", 
                "last_name": "Sunmi Park"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Pharmicell Co., Ltd."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-center, Open-label, Comparison and a Parallel Group Study (3 Groups) Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, in Order to Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI(Autologous Human Bone Marrow Derived Mesenchymal Stem Cells) in AMI Patients, and to Observe the Efficacy of the Second Cell Treatment.", 
        "overall_official": {
            "affiliation": "Severance Hospital, Yonsei University College of Medicine", 
            "last_name": "Yang Soo Jang, Ph.D.  M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Left ventricle ejection fraction (LVEF) measured 13 months after the cell treatment (MRI measurement)", 
            "measure": "LVEF by MRI", 
            "safety_issue": "No", 
            "time_frame": "13 months after the cell treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652209"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pharmicell Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmicell Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}